Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs
- 14 June 2010
- journal article
- Published by Elsevier BV in European Journal of Pharmaceutical Sciences
- Vol. 40 (3), 222-238
- https://doi.org/10.1016/j.ejps.2010.03.018
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Salicylate–urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilitiesBioorganic & Medicinal Chemistry Letters, 2009
- Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolaseCell Biology and Toxicology, 2008
- Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolaseBioorganic & Medicinal Chemistry, 2007
- Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitorsBioorganic & Medicinal Chemistry Letters, 2006
- Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory painLife Sciences, 2006
- Peptidyl-urea based inhibitors of soluble epoxide hydrolasesBioorganic & Medicinal Chemistry Letters, 2006
- The 5-substituted piperazine as a novel secondary pharmacophore greatly improving the physical properties of urea-based inhibitors of soluble epoxide hydrolaseBioorganic & Medicinal Chemistry, 2006
- Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolaseBioorganic & Medicinal Chemistry Letters, 2006
- Development of a high-throughput screen for soluble epoxide hydrolase inhibitionAnalytical Biochemistry, 2006
- High-throughput pharmacokinetic method: Cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysisAnalytica Chimica Acta, 2006